Ciraparantag (PER977): Anticoagulant Reversal Agent
Ciraparantag (PER977) is an intravenously administered synthetic molecule designed by Perosphere as a reversal agent for oral direct Factor Xa inhibitor and low molecular weight heparin anticoagulants.
Anticoagulants are widely used for the prevention and treatment of a variety of thromboembolic events. While oral direct Factor Xa inhibitors exhibit predictable anticoagulant action and improved side effect profiles, they lack a reversal agent. Pharmacologic anticoagulation becomes a clinical problem when anticoagulated patients experience major bleeding, or require emergency surgery -- which is the clinical motivation for developing a reversal agent for these anticoagulants.
Currently there is no approved reversal agent for the oral direct Factor Xa inhibitors or for low molecular weight heparin. Ciraparantag, is an intravenously administered synthetic, small molecule invented by Perosphere aimed at reversing Daiichi Sankyo Co., Ltd.'s Savaysa™/Lixiana® (edoxaban), Johnson & Johnson's and Bayer HealthCare AG's Xarelto® (rivaroxaban) and Bristol-Myers Squibb Company's and Pfizer Inc.'s Eliquis® (apixaban) when medically indicated.
Currently in Phase 2 clinical trials, ciraparantag has demonstrated complete and sustained reversal of Daiichi Sankyo’s SavaysaTM/Lixiana® (edoxaban) and Sanofi’s Lovenox® (enoxaparin sodium sub-cutaneous injection). Furthermore, no pro-coagulant signal has been observed, as measured by D-dimer, F1.2, TFPI or whole blood clotting time in clinical trials. Non-clinical studies have demonstrated reversal of Daiichi Sankyo's SavaysaTM/Lixiana® (edoxaban), Boehringer Ingelheim's Pradaxa® (dabigatran etexilate), Johnson & Johnson and Bayer's Xarelto® (rivaroxaban), Bristol-Myers Squibb and Pfizer's Eliquis® (apixaban) and Sanofi’s Lovenox® (enoxaparin sodium injection). If ciraparantag is shown to be safe and efficacious in humans, it would address this unmet clinical need.